Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
S&P Pharmaceuticals SPDR (NY: XPH)
42.20 USD  +0.23 (+0.55%)
Streaming Delayed Price  /  Updated: 10:00 AM EST, Dec 13, 2019  /  Add to My Watchlist      
View: Quote News
Fund Overview
S&P Pharmaceuticals SPDR
Sector
Exchange Traded NY
Net Assets 322.84M
Inception Date
Related Funds
Quote
Price 42.20
Volume 63,486
Last Trade Dec 13, 10:00am
Change (%)
+0.23 (0.55%)
Prev. Close 41.97
YTD %
+14.33%
Dividend Yield 0.57%
Performance
YTD
+5.29 (14.33%)
1 Month
+4.02 (10.53%)
3 Month
+4.83 (12.92%)
6 Month
+4.41 (11.67%)
1 Year
+0.66 (1.59%)
Chart
Charting
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Is Coiled Volatility Suggesting Big Stock Move?
Options bets suggest that traders may be a bit too unnerved about the risks facing the stock market heading into the end of the year. History suggests that such complacency could come back to bite... Read More
from ETFdb
Markets Bounce Back & Close Week Near Record Highs
U.S. markets closed near record highs for the week, with the Dow Jones Industrial Average up 1.1% week to date, and the S&P 500 and Nasdaq Composite gathering 0.6% and 0.8%, respectively, for the week.... Read More
from ETFdb
Top News
More News
Could Coiled Volatility Suggest A Bigger Stock Move Is Coming?
Options bets suggest that traders may be a bit too unnerved about the risks facing the stock market heading into the end of the year. History suggests that such complacency could come back to bite... Read More
from ETF Trends
Markets Bounce Back to Close Week Near Record Highs
U.S. markets closed near record highs for the week, with the Dow Jones Industrial Average up 1.1% week to date, and the S&P 500 and Nasdaq Composite gathering 0.6% and 0.8%, respectively, for the week.... Read More
from ETF Trends
Pharma ETFs Set To Benefit Post Strong Q3 Earnings
Robust results led to solid trading in pharma ETFs in a month. Here they are in detail. Read More
from Blogs - TalkMarkets
Attractive Market Opportunities
Investors can buy the market as it hits new highs using passive mutual funds or ETFs, or if they don’t want to chase strength they can look to the healthcare sector. There are opportunities for... Read More
from Blogs - TalkMarkets
'Fast Money Halftime Report' Picks For September 25
On CNBC's "Fast Money Halftime Report,"Joe Terranova said that JPMorgan Chase & Co. (NYSE: JPM) is going to ... Read More
from Benzinga
Mallinckrodt’s stock suffers record plunge after report bankruptcy is being considered
Shares of Mallinckrodt PLC were suffering their biggest-ever one-day selloff toward a record low Thursday, after a report that the specialty drug company had hired restructuring advisers and was... Read More
from MarketWatch
8 ETFs to Capture Opportunities in Healthcare Sector
Institutional investors and hedge funds have shifted away from technology names as the U.S.-China trade war extends and picked up battered healthcare names. Retail investors can also gain exposure to... Read More
from ETFdb
8 ETFs to Capture Opportunities in Healthcare Sector
Institutional investors and hedge funds have shifted away from technology names as the U.S.-China trade war extends and picked up battered healthcare names. Retail investors can also gain exposure to... Read More
from ETF Trends
Implied XPH Analyst Target Price: $56
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... Read More
from ETF Channel
4 Hot Pharmaceutical ETFs
Pharmaceutical ETFs invest in stocks of companies that are involved in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. With Johnson and Johnson... Read More
from ETF Trends
AbbVie, Allergan Deal Puts Spotlight on Pharmaceutical ETFs
Pharmaceutical sector-specific exchange traded funds showed mixed results Tuesday after AbbVie (NYSE: ABBV) agreed to acquire Allergan (NYSE: AGN) for $63 billion. Among the largest pharma-specific... Read More
from ETF Trends
Legal Troubles Beset Pharmaceutical Sector ETFs
Pharmaceutical ETFs may be in trouble with legal troubles looming over the industry. The drugmaker segment recently sold-off after an amended civil antitrust complaint brought by more than 40 state... Read More
from ETF Trends
Stocks of generic drug companies fall after more than 40 states file suit alleging price fixing
Forty-four state attorneys general announced the had filed suit against 20 generic drugmakers, including Teva and Mylan. Read More
from MarketWatch
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.